Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $1.6 million.

  • InMed Pharmaceuticals' Total Current Liabilities rose 829.49% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 829.49%. This contributed to the annual value of $1.8 million for FY2025, which is 669.53% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Total Current Liabilities of $1.6 million as of Q3 2025, which was up 829.49% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Total Current Liabilities ranged from a high of $4.6 million in Q4 2021 and a low of $1.3 million during Q3 2023
  • For the 5-year period, InMed Pharmaceuticals' Total Current Liabilities averaged around $2.3 million, with its median value being $1.9 million (2021).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 7031.92% in 2022, then plummeted by 5919.48% in 2023.
  • InMed Pharmaceuticals' Total Current Liabilities (Quarter) stood at $4.6 million in 2021, then plummeted by 48.01% to $2.4 million in 2022, then tumbled by 30.0% to $1.7 million in 2023, then increased by 6.57% to $1.8 million in 2024, then dropped by 13.18% to $1.6 million in 2025.
  • Its Total Current Liabilities stands at $1.6 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.8 million for Q1 2025.